Generic pharmaceutical company DifGen Pharmaceuticals announced on Thursday that it has received approval from the US Food and Drug Administration (FDA) for Fluorometholone Ophthalmic Suspension, 0.1%, a complex generic formulation used to treat eye inflammation.
This is only the second generic FDA approval of this complex suspension product, DifGen said.
Fluorometholone Ophthalmic Suspension is a corticosteroid indicated for treating steroid-responsive inflammatory conditions of the eye's anterior segment.
Ramandeep Singh Jaj and Santhanakrishnan Srinivasan, DifGen Pharmaceuticals founders and co-CEO's, said: "We are extremely proud that we received this first cycle approval, which marks a significant milestone for DifGen, demonstrating our expertise in developing complex ophthalmic suspension products with a high regulatory threshold for demonstration of therapeutic equivalence."
MEDIPOST files IND amendment to start Phase III trial for knee osteoarthritis therapy
DifGen Pharmaceuticals' Fluorometholone Ophthalmic Suspension, 0.1% receives FDA approval
Philips launches InkSpace Imaging Snuggle coil for 3.0T MRI systems
Amgen wins European approval for Uplizna in generalised myasthenia gravis
Arctic Therapeutics enrols first patients in Phase IIa trial of AT-004 for acne vulgaris
BillionToOne launches two new add-on liquid biopsy applications for Northstar Select
Iterion Therapeutics reports first patient dosed in clinical study of tegavivint
FDA accepts Takeda's oveporexton NDA with priority review for narcolepsy type 1
Innocan Pharma reports findings from clinical study of LPT-CBD in dogs
Lunai Bioworks starts new oncology collaboration with clinical-stage partner
Median Technologies secures FDA clearance for AI lung cancer screening software
Sanofi's rilzabrutinib receives FDA breakthrough and Japan orphan designations for rare anaemia
Ascentage Pharma receives China IND clearance for BTK degrader APG‑3288